Monitor upcoming regulatory interactions and Phase 3 trial initiation in early 2027. The favorable safety profile and strong efficacy data position zovegalisib as a potential best-in-class triplet regimen, which could significantly impact Relay's valuation if Phase 3 results are positive.
Price Chart
Executive Summary
Relay Therapeutics announced positive clinical data from the zovegalisib, fulvestrant, and atirmociclib triplet combination trial in heavily pre-treated metastatic breast cancer patients. The data showed a 44% objective response rate and favorable tolerability, supporting advancement into a Phase 3 trial for frontline patients. The company also secured a supply agreement with Pfizer for atirmociclib.
Key Facts
- 44% objective response rate in heavily pre-treated patients with PI3K-mutated, HR+/HER2- metastatic breast cancer
- 77% of patients remain on study with median follow-up of 7.4 months
- Only 3% discontinued treatment due to adverse events
- Phase 3 trial planned for frontline patients, expected to initiate in early 2027
- Pfizer agreed to supply atirmociclib for the Phase 3 trial
Financial Impact
The positive clinical data significantly increases the potential market value of zovegalisib, with estimated US TAM of $7-8B for frontline breast cancer. The Phase 3 advancement reduces development risk.
Risk Factors
- Phase 3 trial results may not replicate Phase 1/2 data
- Competition from existing CDK4/6 inhibitors in frontline setting
- Potential safety issues emerging in larger patient populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179404 |
| Document: 0001193125-26-179404-index.html | 0001193125-26-179404 |
| Document: 0001193125-26-179404.txt | 0001193125-26-179404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $18.66 $18.84 | ▲ +0.96% | ▲ +1.62% | $18.96 (+1.61%) |
Aug 28, 2026 5w ago | Insider Cluster | $18.77 $19.04 | ▼ −1.44% | ▼ −1.33% | $18.96 (−1.01%) |
Aug 18, 2026 6w ago | Insider Cluster | $20.61 $20.57 | ▲ +0.19% | ▼ −0.01% | $18.96 (+8.01%) |
Jul 8, 2026 12w ago | Insider Cluster | $19.63 $19.08 | ▼ −2.80% | ▼ −3.66% | $18.96 (−3.41%) |
Jun 22, 2026 14w ago | 144 | $17.44 $19.74 | ▲ +13.19% | ▲ +12.18% | $18.96 (+8.72%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.81 $15.88 | ▲ +7.22% | ▲ +6.55% | $18.96 (+28.02%) |
May 21, 2026 19w ago | 8-K | $13.53 $14.26 | ▼ −5.40% | ▼ −3.74% | $18.96 (−40.13%) |
May 21, 2026 19w ago | Press Release | $13.66 $14.05 | ▼ −2.86% | ▼ −1.01% | $18.96 (−38.80%) |
May 19, 2026 19w ago | 424B5 | $13.02 $13.90 | ▼ −6.76% | ▼ −4.96% | $18.96 (−45.62%) |
May 19, 2026 19w ago | Press Release | $13.02 $14.43 | ▼ −10.83% | ▼ −9.59% | $18.96 (−45.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access